CDK4 and prostate cancer: We are actively seeking to validate our published prostate cancer PDE data that showed efficacy of CDK4/6 inhibitors [23], through a pharmacodynamic neoadjuvant clinical study of CDK4/6 inhibitors in prostate cancer [30].